Clinical Trial Update: Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating transdermal abaloparatide (BA058) in postmenopausal osteoporosis has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• BA058 (Abaloparatide) transdermal (abaloparatide)

Snippet

Sponsor: Radius Health, Inc. | Conditions: Post Menopausal Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2016-12-19